Overview

Plaquenil for Alopecia Areata, Alopecia Totalis

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). Published evidence says that it is mediated by T-lymphocytes. Plaquenil is an anti-inflammatory drug approved by the FDA for malaria, lupus erythematosus, and rheumatoid arthritis. It has an effect on T-lymphocyte mediated inflammation, making it a logical choice for a treatment trail for alopecia areata.
Phase:
Phase 4
Details
Lead Sponsor:
Hordinsky, Maria K., MD
Treatments:
Hydroxychloroquine